LH
Labcorp Holdings Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +15.4% ·
share flow -17.1% ·
net new positions +13.3%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 158 | +5 | 56.58M | $15.83B | +9 | −3 |
| Q1 2026 | 155 | +1 | 55.32M | $14.74B | +4 | −4 |
| Q4 2025 | 153 | -1 | 61.82M | $15.50B | +1 | −1 |
| Q3 2025 | 19 | 0 | 33.10M | $9.50B | — | −1 |
| Q2 2025 | 17 | -1 | 30.31M | $7.95B | +1 | −2 |
| Q1 2025 | 15 | +2 | 7.94M | $1.85B | +2 | — |
| Q4 2024 | 13 | 0 | 9.58M | $2.20B | +2 | −2 |
| Q3 2024 | 12 | +1 | 4.32M | $962.67M | +2 | −1 |
| Q2 2024 | 11 | — | 5.93M | $1.21B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.83M | +3.3% | $890.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.07M | +3.2% | $479.92M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.07M | +3.2% | $479.92M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 982.97K | -6.0% | $228.78M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 265.25K | +0.7% | $61.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 265.25K | +0.7% | $61.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 265.25K | +0.7% | $61.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 265.25K | +0.7% | $61.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 265.25K | +0.7% | $61.73M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 203.93K | +73.1% | $47.46M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 203.93K | +73.1% | $47.46M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 163.80K | +8.1% | $37.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 163.80K | +8.1% | $37.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 163.80K | +8.1% | $37.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 163.80K | +8.1% | $37.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 163.80K | +8.1% | $37.76M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Point72 Asset Management ✦ | 109.80K | New | $25.55M | 0.1% | New | 1 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 70.10K | +64.4% | $16.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | Marshall Wace ✦ | 69.24K | New | $16.12M | 0.0% | New | 1 | SEC ↗ |
| 20 | Marshall Wace ✦ | 69.24K | New | $16.12M | 0.0% | New | 1 | SEC ↗ |
| 21 | Millennium Management ✦ | 67.44K | -90.4% | $15.70M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 62.82K | +145.0% | $14.62M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 31.38K | -43.7% | $7.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | Bridgewater Associates ✦ | 18.05K | -50.5% | $4.20M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 25 | Citadel Advisors ✦ | 2.31K | -99.8% | $537,164 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 26 | Fisher Asset Management ✦ | 1.83K | -10.1% | $425,566 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $25.55M | 0.1% |
| Marshall Wace | $16.12M | 0.0% |
| Marshall Wace | $16.12M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,014 holders, 76.41M shares, $19.36B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.00K sh · $954,060
Officer, Director · 4.67K sh · $1.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology